- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Consolidated Financial Summary**
In the recent board meeting, Akums Drugs and Pharmaceuticals Limited disclosed its financial results for the quarter and nine months ended December 31, 2024. The consolidated revenue from operations was ₹10,104.11 million, a decrease from ₹10,828.35 million in the same quarter last year, indicating a year-over-year decline of approximately 6.67%. This contraction could be attributed to fluctuations in demand and potential supply chain challenges.
The total income for the quarter was recorded at ₹10,249.72 million. The company reported a net profit before tax of ₹910.53 million, reflecting a significant improvement from a loss of ₹452.78 million in the previous year, primarily driven by effective cost management and operational optimizations. Earnings Per Share (EPS) stood at ₹4.26, compared to ₹1.32 in the corresponding previous quarter, signaling strong recovery.
Total operational expenses were ₹9,387.00 million, with major expenditures linked to materials consumed at ₹5,645.98 million and employee benefits at ₹1,755.98 million. A careful review of cost structure appears to enhance profit margins, particularly through critical areas such as finance costs that were reduced to ₹513.04 million.
The balance sheet remains robust, with assets totaling ₹38,662.71 million against liabilities of ₹9,528.11 million, indicating a healthy equity position. Looking forward, the company is focused on expanding its R&D capabilities and developing international markets through new subsidiaries in the UK and Malta.
**Investor Insight:** Given the operational efficiencies and strategic investments planned, a hold position is suggested while monitoring revenue recovery in the upcoming quarters and the potential impact of any regulatory challenges ahead.
All announcements from Akums Drugs and Pharmaceuticals Limited